The Biomolecular Resource Laboratory (BRL) is a heavily used core service laboratory of the Comprehensive Cancer Center that supported the research laboratory activities of 41 Cancer Center members during fiscal year 2005. The BRL provides strategically important analytical services to Center members for 1) characterization of DMA, peptides, proteins and 2) identification and quantification of lipids, proteins, and peptides. These services include five different types of mass spectrometry for analysis of proteins, peptides and lipids, automated DNA sequence analysis, synthesis of RNA and DNA oligonucleotides, purification of peptides and proteins, and chemical synthesis of peptides. The BRL analyzed more than 14,000 samples during the reporting period. DNA sequence analysis (7924 samples) and mass spectrometry (6403 samples) were the most heavily used core services in the BRL. The protein/peptide and DNA chemical services accounted for an additional 956 samples. Laboratories of Cancer Center members received 49% of the services performed in the BRL during fiscal year 2005. The BRL has expanded significantly since the last review. Mass spectrometry services have been added to meet the significant needs of Cancer Center members for metabolomics and proteomics. During the last funding period, three new mass spectrometers were added to the facility. These included two Bruker mass spectrometers (an Autoflex MALDI-TOF and an Esquire HCT ion trap) and a Waters/Micromass Quadrupole Time-of-flight (Q-TOF) mass spectrometer, specifically to enhance the study of proteins and lipids. Dr. Michael Thomas, a leading expert in the analysis of lipids and lipid metabolites by mass spectrometry, has joined the laboratory as a co-director with Dr. Mark Lively. The addition of Dr. Thomas, and his staff and instrumentation, has enhanced the ability of the BRL to meet the needs of the Cancer Center program members in the especially important areas of proteomics and metabolomics. Together, Drs. Lively and Thomas provide significant expertise in biochemistry of proteins and DNA, mass spectrometry, and analytical methods to enhance and promote cancer research in the CCCWFU.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-33
Application #
7578255
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-02-01
Budget End
2009-01-31
Support Year
33
Fiscal Year
2008
Total Cost
$166,390
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Bolduc, Jesalyn A; Nelson, Kimberly J; Haynes, Alexina C et al. (2018) Novel hyperoxidation resistance motifs in 2-Cys peroxiredoxins. J Biol Chem 293:11901-11912
Farris, Michael; McTyre, Emory R; Okoukoni, Catherine et al. (2018) Cortical Thinning and Structural Bone Changes in Non-Human Primates after Single-Fraction Whole-Chest Irradiation. Radiat Res 190:63-71
Petty, W Jeffrey; Urbanic, James J; Ahmed, Tamjeed et al. (2018) Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 102:527-535
Garland, Mary; Addis, Dylan; Russell, Greg et al. (2018) The Effect of Regional Anesthesia on Oncologic Outcomes after Resection of Colorectal Hepatic Metastases. Am Surg 84:e29-32
Dutta, Samrat; Rivetti, Claudio; Gassman, Natalie R et al. (2018) Analysis of single, cisplatin-induced DNA bends by atomic force microscopy and simulations. J Mol Recognit 31:e2731
Paek, M-S; Nightingale, C L; Tooze, J A et al. (2018) Contextual and stress process factors associated with head and neck cancer caregivers' physical and psychological well-being. Eur J Cancer Care (Engl) 27:e12833
Atkins, Hannah M; Appt, Susan E; Taylor, Robert N et al. (2018) Systemic Iron Deficiency in a Nonhuman Primate Model of Endometriosis. Comp Med 68:298-307
Pardee, Timothy S; Anderson, Rebecca G; Pladna, Kristin M et al. (2018) A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res 24:2060-2073
Yang, M; Forbes, M E; Bitting, R L et al. (2018) Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol 29:311-323
Godwin, Ryan C; Gmeiner, William H; Salsbury Jr, Freddie R (2018) All-atom molecular dynamics comparison of disease-associated zinc fingers. J Biomol Struct Dyn 36:2581-2594

Showing the most recent 10 out of 548 publications